KR20070072608A - 유전자 변형된 면역계를 가지는 유제류 - Google Patents
유전자 변형된 면역계를 가지는 유제류 Download PDFInfo
- Publication number
- KR20070072608A KR20070072608A KR1020077011667A KR20077011667A KR20070072608A KR 20070072608 A KR20070072608 A KR 20070072608A KR 1020077011667 A KR1020077011667 A KR 1020077011667A KR 20077011667 A KR20077011667 A KR 20077011667A KR 20070072608 A KR20070072608 A KR 20070072608A
- Authority
- KR
- South Korea
- Prior art keywords
- immunoglobulin
- ungulate
- seq
- cells
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000987 immune system Anatomy 0.000 title description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 295
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 295
- 241000282898 Sus scrofa Species 0.000 claims abstract description 156
- 238000000034 method Methods 0.000 claims abstract description 149
- 241001465754 Metazoa Species 0.000 claims abstract description 143
- 230000014509 gene expression Effects 0.000 claims abstract description 98
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 62
- 210000000056 organ Anatomy 0.000 claims abstract description 21
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims abstract description 17
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 300
- 108090000623 proteins and genes Proteins 0.000 claims description 291
- 239000012634 fragment Substances 0.000 claims description 182
- 210000004507 artificial chromosome Anatomy 0.000 claims description 161
- 108020004414 DNA Proteins 0.000 claims description 152
- 230000008685 targeting Effects 0.000 claims description 142
- 239000013598 vector Substances 0.000 claims description 139
- 239000002773 nucleotide Substances 0.000 claims description 118
- 125000003729 nucleotide group Chemical group 0.000 claims description 118
- 230000009261 transgenic effect Effects 0.000 claims description 92
- 108700028369 Alleles Proteins 0.000 claims description 70
- 210000000349 chromosome Anatomy 0.000 claims description 67
- 229940072221 immunoglobulins Drugs 0.000 claims description 62
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 210000001106 artificial yeast chromosome Anatomy 0.000 claims description 55
- 210000003917 human chromosome Anatomy 0.000 claims description 53
- 239000000427 antigen Substances 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 108010052160 Site-specific recombinase Proteins 0.000 claims description 44
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 210000000723 mammalian artificial chromosome Anatomy 0.000 claims description 36
- 241000283690 Bos taurus Species 0.000 claims description 32
- 210000002950 fibroblast Anatomy 0.000 claims description 32
- 239000003550 marker Substances 0.000 claims description 32
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 27
- 239000003623 enhancer Substances 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 23
- 210000004602 germ cell Anatomy 0.000 claims description 21
- 238000012239 gene modification Methods 0.000 claims description 20
- 230000005017 genetic modification Effects 0.000 claims description 20
- 235000013617 genetically modified food Nutrition 0.000 claims description 20
- 239000000839 emulsion Substances 0.000 claims description 18
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 16
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 15
- 210000001082 somatic cell Anatomy 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 8
- 241000283707 Capra Species 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 230000006911 nucleation Effects 0.000 claims description 6
- 238000010899 nucleation Methods 0.000 claims description 6
- 210000002308 embryonic cell Anatomy 0.000 claims description 3
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 claims description 2
- 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 210000004995 male reproductive system Anatomy 0.000 claims description 2
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 claims 2
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 22
- 238000011160 research Methods 0.000 abstract description 8
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 124
- 210000000287 oocyte Anatomy 0.000 description 54
- 206010028980 Neoplasm Diseases 0.000 description 47
- 241000282887 Suidae Species 0.000 description 40
- 239000013615 primer Substances 0.000 description 39
- 230000006798 recombination Effects 0.000 description 39
- 238000005215 recombination Methods 0.000 description 39
- 238000002744 homologous recombination Methods 0.000 description 37
- 230000006801 homologous recombination Effects 0.000 description 37
- 238000012546 transfer Methods 0.000 description 36
- 201000011510 cancer Diseases 0.000 description 33
- 108010091086 Recombinases Proteins 0.000 description 32
- 102000018120 Recombinases Human genes 0.000 description 32
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 31
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 31
- 230000002068 genetic effect Effects 0.000 description 26
- 230000004927 fusion Effects 0.000 description 23
- 230000000295 complement effect Effects 0.000 description 22
- 238000003780 insertion Methods 0.000 description 22
- 230000008569 process Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 210000001671 embryonic stem cell Anatomy 0.000 description 20
- 230000001605 fetal effect Effects 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 20
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 230000037431 insertion Effects 0.000 description 19
- 210000004962 mammalian cell Anatomy 0.000 description 19
- 230000001404 mediated effect Effects 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000008707 rearrangement Effects 0.000 description 18
- 241000282412 Homo Species 0.000 description 17
- 238000010367 cloning Methods 0.000 description 17
- 230000010354 integration Effects 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 210000004940 nucleus Anatomy 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 238000013459 approach Methods 0.000 description 16
- 241000894007 species Species 0.000 description 16
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 230000010076 replication Effects 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 108020005065 3' Flanking Region Proteins 0.000 description 13
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 13
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 13
- 239000003337 fertilizer Substances 0.000 description 13
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 238000010363 gene targeting Methods 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 210000004102 animal cell Anatomy 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 241001529936 Murinae Species 0.000 description 10
- 238000009395 breeding Methods 0.000 description 10
- 230000001488 breeding effect Effects 0.000 description 10
- 208000031513 cyst Diseases 0.000 description 10
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 108020005029 5' Flanking Region Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108010051219 Cre recombinase Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000000520 microinjection Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 101150008942 J gene Proteins 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 101150117115 V gene Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000002759 chromosomal effect Effects 0.000 description 7
- 101150036876 cre gene Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000010449 nuclear transplantation Methods 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 108010046276 FLP recombinase Proteins 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001476 gene delivery Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 230000011278 mitosis Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 210000003101 oviduct Anatomy 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000000392 somatic effect Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 230000006370 G0 arrest Effects 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 101150097493 D gene Proteins 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- 241000702191 Escherichia virus P1 Species 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 108010061833 Integrases Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 101100343701 Mus musculus Loxl1 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 108010058731 nopaline synthase Proteins 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 210000004508 polar body Anatomy 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 229940050570 regu-mate Drugs 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 241001550206 Colla Species 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 241000255969 Pieris brassicae Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 108020004487 Satellite DNA Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229960000971 altrenogest Drugs 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- -1 as well as pollen Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000012173 estrus Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108010000700 Acetolactate synthase Proteins 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193388 Bacillus thuringiensis Species 0.000 description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- 108010013423 CMPacetylneuraminate monooxygenase Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101100485230 Campylobacter jejuni subsp. jejuni serotype O:2 (strain ATCC 700819 / NCTC 11168) xerH gene Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000702197 Enterobacteria phage P4 Species 0.000 description 2
- 241000701968 Enterobacteria phage phi80 Species 0.000 description 2
- 241001147440 Escherichia virus 186 Species 0.000 description 2
- 241000702192 Escherichia virus P2 Species 0.000 description 2
- 108010019236 Fucosyltransferases Proteins 0.000 description 2
- 102000006471 Fucosyltransferases Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 2
- 108010056307 Hin recombinase Proteins 0.000 description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 2
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000012330 Integrases Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000701835 Salmonella virus P22 Species 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 2
- 101150050575 URA3 gene Proteins 0.000 description 2
- 108010078072 VDJ Recombinases Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000011230 antibody-based therapy Methods 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 229940097012 bacillus thuringiensis Drugs 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 108010087471 cin recombinase Proteins 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000010502 episomal replication Effects 0.000 description 2
- 230000001158 estrous effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 101150042777 flp gene Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000000003 hoof Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940065638 intron a Drugs 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000000415 mammalian chromosome Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- 101150060755 xerC gene Proteins 0.000 description 2
- 101150005813 xerD gene Proteins 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101100111164 Arabidopsis thaliana BAC2 gene Proteins 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241001147386 Bos sp. Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710115643 Cathelicidin-1 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000483002 Euproctis similis Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 101150099983 GT gene Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010091714 Globoside alpha-N-acetylgalactosaminyltransferase Proteins 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- JMENXJYBCQFIRK-KRJDXUSZSA-N N-hexacosanoylisoglobotriaosyl ceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 JMENXJYBCQFIRK-KRJDXUSZSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 101150071716 PCSK1 gene Proteins 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108010078334 UDP-galactose beta-D-galactosyl-1,4-glycosylceramide alpha-1,3-galactosyltransferase Proteins 0.000 description 1
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 230000007720 allelic exclusion Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004718 centriole Anatomy 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 102000044446 human CD46 Human genes 0.000 description 1
- 102000051442 human CD59 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000002415 kinetochore Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002596 lutein cell Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000004179 neuropil Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920003987 resole Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000002427 ring chromosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/101—Bovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/102—Caprine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/103—Ovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62143304P | 2004-10-22 | 2004-10-22 | |
| US60/621,433 | 2004-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070072608A true KR20070072608A (ko) | 2007-07-04 |
Family
ID=36228428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077011667A Withdrawn KR20070072608A (ko) | 2004-10-22 | 2005-10-24 | 유전자 변형된 면역계를 가지는 유제류 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060130157A1 (enExample) |
| EP (2) | EP1811832A4 (enExample) |
| JP (5) | JP2008517608A (enExample) |
| KR (1) | KR20070072608A (enExample) |
| CN (1) | CN101389214A (enExample) |
| AU (1) | AU2005299413A1 (enExample) |
| CA (3) | CA2585098C (enExample) |
| ES (1) | ES2679282T3 (enExample) |
| NZ (1) | NZ554824A (enExample) |
| WO (1) | WO2006047603A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074983B2 (en) * | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
| AU1777301A (en) * | 1999-11-19 | 2001-05-30 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
| US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
| AU2003290689A1 (en) * | 2002-11-08 | 2004-06-03 | Kyowa Hakko Kirin Co., Ltd. | Transgenic ungulates having reduced prion protein activity and uses thereof |
| CA2563064A1 (en) | 2004-04-22 | 2005-11-10 | Kirin Beer Kabushiki Kaisha | Transgenic animals and uses thereof |
| US20080026457A1 (en) * | 2004-10-22 | 2008-01-31 | Kevin Wells | Ungulates with genetically modified immune systems |
| CA2617930A1 (en) | 2005-08-09 | 2007-03-29 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
| EP2602323B1 (en) * | 2007-06-01 | 2018-02-28 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
| JP5511144B2 (ja) * | 2008-02-12 | 2014-06-04 | 学校法人福岡大学 | てんかんモデル非ヒト哺乳動物 |
| DK2348827T3 (en) | 2008-10-27 | 2015-07-20 | Revivicor Inc | IMMUNICIPLY COMPROMATED PETS |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| US10920242B2 (en) | 2011-02-25 | 2021-02-16 | Recombinetics, Inc. | Non-meiotic allele introgression |
| EP3450563A1 (en) * | 2011-02-25 | 2019-03-06 | Recombinetics, Inc. | Genetically modified animals and methods for making the same |
| PT2931030T (pt) * | 2012-12-14 | 2020-08-03 | Open Monoclonal Tech Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
| MX2016014066A (es) * | 2014-04-28 | 2017-05-03 | Recombinetics Inc | Edicion de genes multiples en cerdos. |
| US11725044B2 (en) * | 2014-10-15 | 2023-08-15 | Xenothera | Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity |
| EP4056031A1 (en) * | 2016-08-11 | 2022-09-14 | The Jackson Laboratory | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |
| CN109906272A (zh) * | 2016-10-31 | 2019-06-18 | 国立大学法人鸟取大学 | 产生人抗体的非人动物和使用该非人动物的人抗体制作方法 |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| US10799614B2 (en) | 2018-10-05 | 2020-10-13 | Xenotherapeutics, Inc. | Xenotransplantation products and methods |
| CN112961863B (zh) * | 2019-06-04 | 2023-03-10 | 中国农业科学院兰州兽医研究所 | 猪IgA类别转换后转录本α长、短序列 |
| CN111154889B (zh) * | 2020-01-16 | 2021-08-03 | 广西扬翔股份有限公司 | 一种与猪体重相关的snp分子标记及其应用和获取方法 |
| CN115918611B (zh) * | 2021-10-25 | 2025-06-27 | 百奥赛图(北京)医药科技股份有限公司 | Tgfbr2基因人源化非人动物及其构建方法和应用 |
| CN116076438B (zh) * | 2023-03-21 | 2024-01-30 | 湖南中医药大学 | 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用 |
| CN119785879B (zh) * | 2024-11-27 | 2025-11-14 | 兰州大学 | 基于多组学策略锁定与绵羊尾脂重相关分子标记的方法及应用 |
Family Cites Families (215)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615374A (en) | 1898-12-06 | Ditch in g atxac h m e nt fo r p lows | ||
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4994384A (en) | 1986-12-31 | 1991-02-19 | W. R. Grace & Co.-Conn. | Multiplying bovine embryos |
| US4889806A (en) | 1987-04-15 | 1989-12-26 | Washington University | Large DNA cloning system based on yeast artificial chromosomes |
| US5057420A (en) | 1987-06-05 | 1991-10-15 | Granada Biosciences, Inc. | Bovine nuclear transplantation |
| HUT55052A (en) | 1988-03-24 | 1991-04-29 | Gen Hospital Corp | Process for producing artificial chromosome vector |
| US5270201A (en) | 1988-03-24 | 1993-12-14 | The General Hospital Corporation | Artificial chromosome vector |
| EP0435928A1 (en) | 1988-09-21 | 1991-07-10 | Animal Biotechnology Cambridge Limited | Derivation of pluripotential embryonic cell lines from domestic animals |
| GB8823068D0 (en) | 1988-09-30 | 1988-11-09 | Ici Plc | Recombinant dna |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US4944384A (en) | 1989-01-30 | 1990-07-31 | Hay & Forage Industries | Trash discharge apparatus for crop transferring conveyor mechanism |
| US4997384A (en) | 1989-04-17 | 1991-03-05 | Otis Engineering Corporation | Wet connector |
| GB8920211D0 (en) | 1989-09-07 | 1989-10-18 | Ici Plc | Diagnostic method |
| WO1991006667A1 (en) | 1989-11-06 | 1991-05-16 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| CA2086092A1 (en) | 1990-07-13 | 1992-01-14 | Douglas A. Treco | Library screening method |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) * | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5382524A (en) | 1990-10-24 | 1995-01-17 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-n-acetylgalactosaminidase |
| ATE204328T1 (de) | 1991-03-11 | 2001-09-15 | Syngenta Ltd | Biozide proteine |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5288625A (en) | 1991-09-13 | 1994-02-22 | Biologic Research Center Of The Hungarian Academy Of Sciences | Mammalian artificial chromosomes |
| WO1993008270A1 (en) | 1991-10-15 | 1993-04-29 | Agracetus, Inc. | Particle-mediated transformation of mammalian unattached cells |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| US5496720A (en) | 1993-02-10 | 1996-03-05 | Susko-Parrish; Joan L. | Parthenogenic oocyte activation |
| WO1994023049A2 (en) | 1993-04-02 | 1994-10-13 | The Johns Hopkins University | The introduction and expression of large genomic sequences in transgenic animals |
| GB9308271D0 (en) | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6096878A (en) | 1993-05-10 | 2000-08-01 | Japan Tobacco Inc. | Human immunoglobulin VH gene segments and DNA fragments containing the same |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US5851760A (en) | 1993-06-15 | 1998-12-22 | The Salk Institute For Biological Studies | Method for generation of sequence sampled maps of complex genomes |
| WO1995003400A1 (en) | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
| JPH09502965A (ja) | 1993-08-20 | 1997-03-25 | ユニバーシティー オブ メディスン アンド デンティストリー オブ ニュー ジャージー | インターフェロンガンマの副因子機能およびその受容体 |
| US5597694A (en) | 1993-10-07 | 1997-01-28 | Massachusetts Institute Of Technology | Interspersed repetitive element-bubble amplification of nucleic acids |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| JPH09509046A (ja) | 1993-11-29 | 1997-09-16 | ユニヴァーシティ オブ サウス フロリダ | トランスジェニックマウス |
| WO1996001276A1 (en) | 1994-07-06 | 1996-01-18 | University Of Medicine & Dentistry Of New Jersey | Expression of a functional human type i interferon receptor |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US5733744A (en) | 1995-01-13 | 1998-03-31 | Cornell Research Foundation, Inc. | Binary BAC vector |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6682729B1 (en) | 1995-05-03 | 2004-01-27 | University Of Maryland, Baltimore | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US6150170A (en) | 1998-05-03 | 2000-11-21 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same |
| US5985846A (en) | 1995-06-07 | 1999-11-16 | Baylor College Of Medicine | Gene therapy for muscular dystrophy |
| US6348353B1 (en) | 1995-06-07 | 2002-02-19 | Case Western Reserve University | Artificial mammalian chromosome |
| US6455254B1 (en) | 1995-07-18 | 2002-09-24 | Diversa Corporation | Sequence based screening |
| JP2000513923A (ja) | 1995-07-18 | 2000-10-24 | ワシントン・ユニバーシティ | 変異ｓ１８２遺伝子 |
| WO1997004111A1 (en) | 1995-07-21 | 1997-02-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | RecA-ASSISTED CLONING OF DNA |
| CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| US6166288A (en) | 1995-09-27 | 2000-12-26 | Nextran Inc. | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor |
| US6133503A (en) | 1995-10-31 | 2000-10-17 | The Regents Of The University Of California | Mammalian artificial chromosomes and methods of using same |
| WO1997016533A1 (en) | 1995-10-31 | 1997-05-09 | The Regents Of The University Of California | Mammalian artificial chromosomes and methods of using same |
| US6150160A (en) | 1995-11-16 | 2000-11-21 | The John Hopkins University | Compositions and methods of use of mammalian retrotransposons |
| US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
| US5866404A (en) | 1995-12-06 | 1999-02-02 | Yale University | Yeast-bacteria shuttle vector |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US20020132295A1 (en) | 1996-02-09 | 2002-09-19 | Short Jay M. | Enzymes having transaminase and aminotransferase activity and methods of use thereof |
| US7288400B2 (en) | 1996-02-16 | 2007-10-30 | Verenium Corporation | Nucleic acids encoding esterases and methods of making and using them |
| US6987016B2 (en) | 1996-03-08 | 2006-01-17 | Diversa Corporation | α-galactosidases and methods for making and using them |
| WO1997037020A1 (en) | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US6077697A (en) | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US6495318B2 (en) | 1996-06-17 | 2002-12-17 | Vectorobjects, Llc | Method and kits for preparing multicomponent nucleic acid constructs |
| US20020137185A1 (en) | 1996-06-17 | 2002-09-26 | Jay Short | Enzymes having amidase activity and methods of use thereof |
| DE69719409T2 (de) | 1996-06-18 | 2004-01-15 | Rikagaku Kenkyusho | Verfahren zur Reinigung von DNS |
| US20020102680A1 (en) | 1996-07-03 | 2002-08-01 | Robertson Dan E. | Catalases |
| JP2000515011A (ja) | 1996-07-09 | 2000-11-14 | アメリカ合衆国 | 形質転換関連組換えクローニング |
| CN1230989A (zh) | 1996-08-19 | 1999-10-06 | 马萨诸塞大学 | 通过种间核移植制备胚胎细胞或干细胞样细胞系 |
| US6017755A (en) | 1996-08-22 | 2000-01-25 | Hsc Research & Development Limited | MADR2 tumour suppressor gene |
| EP2060633A1 (en) | 1996-08-26 | 2009-05-20 | Chromo Research, Inc. | Mammalian artificial chromosomes |
| US6187533B1 (en) | 1996-09-10 | 2001-02-13 | Arch Development Corporation | Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α |
| US6294712B1 (en) | 1996-09-18 | 2001-09-25 | Christian Jung | Nematode-resistant gene |
| WO1998012336A1 (en) | 1996-09-18 | 1998-03-26 | Dnavec Research Inc. | Artificial chromosome |
| US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
| US6020142A (en) | 1996-10-04 | 2000-02-01 | Millennium Pharmaceuticals, Inc. | Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders |
| US6136566A (en) | 1996-10-04 | 2000-10-24 | Lexicon Graphics Incorporated | Indexed library of cells containing genomic modifications and methods of making and utilizing the same |
| US6287854B1 (en) | 1996-10-22 | 2001-09-11 | Imperial Cancer Research Technology Limited | Diagnosis of susceptibility to cancer and treatment thereof |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US7279316B2 (en) | 1996-12-06 | 2007-10-09 | Verenium Corporation | Enzymes having glycosidase activity and methods of use thereof |
| US6358523B1 (en) | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
| CA2274306A1 (en) | 1996-12-16 | 1998-06-25 | Mcgill University | Human and mammalian dna replication origin consensus sequences |
| GB9702802D0 (en) | 1997-02-12 | 1997-04-02 | Babraham The Inst | Yeast artificial chromosomes |
| WO1998040510A1 (en) | 1997-03-11 | 1998-09-17 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
| JP3151657B2 (ja) | 1997-03-26 | 2001-04-03 | 農林水産省農業生物資源研究所長 | 遺伝子導入法 |
| ES2513043T3 (es) | 1997-03-26 | 2014-10-24 | Imperial Innovations Limited | Proteína de fusión anticoagulante anclada a membrana de la célula |
| US5843671A (en) | 1997-04-01 | 1998-12-01 | Princeton University | Methods for measuring trinucleotide repeat expansion in Saccharomyces cerevisiae |
| AU741630B2 (en) | 1997-05-07 | 2001-12-06 | Genomics One Corporation | Improved cloning vector containing marker inactivation system |
| EP0996719A4 (en) | 1997-05-13 | 2002-05-08 | Amrad Operations Pty Ltd | A novel nucleic acid molecule |
| US5972649A (en) | 1997-05-29 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Polynucleotide sequence encoding human multiple endocrine neoplasia type 1 protein |
| US6156953A (en) | 1997-06-03 | 2000-12-05 | University Of Chicago | Plant artificial chromosome compositions and methods |
| US6156574A (en) | 1997-06-23 | 2000-12-05 | The Rockefeller University | Methods of performing gene trapping in bacterial and bacteriophage-derived artificial chromosomes and use thereof |
| US6143566A (en) | 1997-06-23 | 2000-11-07 | The Rockfeller University | Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof |
| US6136952A (en) | 1997-06-25 | 2000-10-24 | University Of Washington | Human jagged polypeptide, encoding nucleic acids and methods of use |
| US6207648B1 (en) | 1997-07-24 | 2001-03-27 | Trustees Of Boston University | Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy |
| US7056703B2 (en) | 1997-08-06 | 2006-06-06 | Diversa Corporation | Polypeptides having polymerase activity and methods of use thereof |
| US6855365B2 (en) | 1997-08-13 | 2005-02-15 | Diversa Corporation | Recombinant bacterial phytases and uses thereof |
| US6090584A (en) | 1997-08-21 | 2000-07-18 | University Technologies International Inc. | Baculovirus artificial chromosomes and methods of use |
| IL135242A0 (en) | 1997-09-26 | 2001-05-20 | Athersys Inc | Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna |
| US5874259A (en) | 1997-11-21 | 1999-02-23 | Wisconsin Alumni Research Foundation | Conditionally amplifiable BAC vector |
| US6485910B1 (en) | 1998-02-09 | 2002-11-26 | Incyte Genomics, Inc. | Ras association domain containing protein |
| US6277621B1 (en) | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
| US6080576A (en) | 1998-03-27 | 2000-06-27 | Lexicon Genetics Incorporated | Vectors for gene trapping and gene activation |
| GB9807520D0 (en) | 1998-04-09 | 1998-06-10 | Univ Wales Medicine | Modified biological material |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6183957B1 (en) | 1998-04-16 | 2001-02-06 | Institut Pasteur | Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria |
| GB9809280D0 (en) | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
| CA2340622A1 (en) | 1998-05-06 | 1999-11-11 | Genprofile Ag | Method for non-radioactive detection of membrane-bonded nucleic acids and test kit |
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| US6004804A (en) | 1998-05-12 | 1999-12-21 | Kimeragen, Inc. | Non-chimeric mutational vectors |
| US6534262B1 (en) | 1998-05-14 | 2003-03-18 | Whitehead Institute For Biomedical Research | Solid phase technique for selectively isolating nucleic acids |
| AUPP388298A0 (en) | 1998-06-03 | 1998-06-25 | Polychip Pharmaceuticals Pty Ltd | Precursers of pharmaceutical compounds |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| WO2000000609A2 (en) | 1998-06-29 | 2000-01-06 | Incyte Pharmaceuticals, Inc. | Molecules associated with apoptosis |
| US6689606B2 (en) | 1998-07-21 | 2004-02-10 | M.L. Laboratories Plc | Polynucleotide |
| AU5217599A (en) | 1998-07-27 | 2000-02-21 | Genotypes, Inc. | Automatic eukaryotic artificial chromosome vector |
| BR9913643A (pt) | 1998-08-11 | 2001-09-25 | Univ Hawaii | Transgênese de mamìferos através de injeção intracitoplásmica de espermatozóides |
| US6673909B1 (en) | 1998-08-25 | 2004-01-06 | The General Hospital Corporation | Oligonucleotides for dysferlin, a gene mutated in distal myopathy and limb girdle muscular dystrophy |
| GB9821193D0 (en) | 1998-09-30 | 1998-11-25 | Medical Res Council | Mammalian artificial chromosomes and uses thereof |
| US6632934B1 (en) | 1998-09-30 | 2003-10-14 | Board Of Regents, The University Of Texas System | MORC gene compositions and methods of use |
| US6743906B1 (en) | 1998-10-02 | 2004-06-01 | Board Of Regents, The University Of Texas | PPP2R1B is a tumor suppressor |
| GB9825555D0 (en) | 1998-11-20 | 1999-01-13 | Imp College Innovations Ltd | Suppression of xenotransplant rejection |
| WO2000034497A2 (en) | 1998-12-09 | 2000-06-15 | The General Hospital Corporation | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| EP1144631A3 (en) | 1999-01-07 | 2002-01-30 | Incyte Pharmaceuticals, Inc. | Insulin-synthesis genes |
| US20020015950A1 (en) | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
| AU780754B2 (en) | 1999-03-04 | 2005-04-14 | Revivicor Inc | Genetic modification of somatic cells and uses thereof |
| GB9909446D0 (en) | 1999-04-23 | 1999-06-23 | Medical Res Council | Vector |
| US6544768B1 (en) | 1999-05-11 | 2003-04-08 | Cornell Research Foundation, Inc. | Mammalian soluble adenylyl cyclase |
| US6284882B1 (en) | 1999-06-10 | 2001-09-04 | Abbott Laboratories | Myostatin gene promoter and inhibition of activation thereof |
| FR2795093B1 (fr) | 1999-06-21 | 2003-08-22 | Inst Rech Developpement Ird | Moyens pour l'identification du locus d'un gene majeur de la resistance au virus de la panachure jaune du riz et leurs applications |
| JP2003180356A (ja) | 1999-07-09 | 2003-07-02 | Mitsubishi Chemicals Corp | アトピー遺伝子 |
| AU6229800A (en) | 1999-07-20 | 2001-02-05 | Rockefeller University, The | Conditional homologous recombination of large genomic vector inserts |
| US6475752B1 (en) | 1999-07-30 | 2002-11-05 | Incyte Genomics, Inc. | Mammalian imidazoline receptor |
| US7074983B2 (en) | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
| AU1777301A (en) | 1999-11-19 | 2001-05-30 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
| US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
| ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
| AUPQ462599A0 (en) | 1999-12-13 | 2000-01-13 | Polychip Pharmaceuticals Pty Ltd | Yeast-based process for production of l-pac |
| CA2394600A1 (en) | 1999-12-17 | 2001-06-21 | Oregon Health And Science University | Methods for producing transgenic animals |
| US6458561B1 (en) | 2000-03-13 | 2002-10-01 | Incyte Genomics, Inc. | Human NIM1 kinase |
| US6492577B1 (en) | 2000-03-16 | 2002-12-10 | The Regents Of The University Of California | Leafy cotyledon2 genes and their uses |
| JP2003530113A (ja) | 2000-04-07 | 2003-10-14 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 新規な染色体性ベクターおよびその用途 |
| WO2002000842A2 (en) | 2000-06-23 | 2002-01-03 | The University Of Chicago | Methods for isolating centromere dna |
| WO2002000916A2 (en) | 2000-06-28 | 2002-01-03 | California Institute Of Technology | Methods for identifying an essential gene in a prokaryotic microorganism |
| US6548256B2 (en) | 2000-07-14 | 2003-04-15 | Eppendorf 5 Prime, Inc. | DNA isolation method and kit |
| US6610006B1 (en) | 2000-07-25 | 2003-08-26 | C. R. Bard, Inc. | Implantable prosthesis |
| US6730500B1 (en) | 2000-08-30 | 2004-05-04 | Zymogenetics, Inc. | Methods for generating a continuous nucleotide sequence from noncontiguous nucleotide sequences |
| WO2002031202A2 (en) | 2000-10-10 | 2002-04-18 | Thomas Jefferson University | High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds |
| US6692954B1 (en) | 2000-11-03 | 2004-02-17 | The Scripps Research Institute | Generation of human cytomegalovirus yeast artificial chromosome recombinants |
| WO2002070648A2 (en) * | 2000-11-17 | 2002-09-12 | Hematech, Llc | Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates |
| US6448041B1 (en) | 2000-12-18 | 2002-09-10 | Incyte Genomics, Inc. | Colon cancer marker |
| AU2002226307A1 (en) | 2001-01-25 | 2002-08-06 | Evolva Biotech A/S | Artificial chromosomes comprising concatemers of expressible nucleotide sequences |
| WO2002059296A2 (en) | 2001-01-25 | 2002-08-01 | Evolva Biotech A/S | Concatemers of differentially expressed multiple genes |
| WO2002061073A2 (en) | 2001-01-30 | 2002-08-08 | Thomas Jefferson University | Mutwnt fish for genetic screebibg of lipid and cholesterol metabolism |
| US20020108132A1 (en) | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
| US7323336B2 (en) | 2001-02-21 | 2008-01-29 | Verenium Corporation | Enzymes having alpha amylase activity and methods of use thereof |
| WO2002070696A2 (en) | 2001-03-07 | 2002-09-12 | Andre Schuh | Cd109 nucleic acid molecules polypeptides and methods of use |
| US6936469B2 (en) | 2001-03-22 | 2005-08-30 | Chromos Molecular Systems Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| NZ527972A (en) | 2001-03-22 | 2006-04-28 | Chromos Molecular Systems Inc | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| US20030186390A1 (en) | 2001-03-22 | 2003-10-02 | De Jong Gary | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| US6455026B1 (en) | 2001-03-23 | 2002-09-24 | Agy Therapeutics, Inc. | Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors |
| AU2002303277A1 (en) | 2001-04-06 | 2002-10-21 | Vladimir Larionov | Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells |
| US6472177B1 (en) | 2001-04-23 | 2002-10-29 | Wisconsin Alumni Research Foundation | Expression vector with dual control of replication and transcription |
| EP1385859A2 (en) | 2001-05-10 | 2004-02-04 | Baylor College Of Medicine | Compositions and methods for array-based genomic nucleic acid analysis of biological molecules |
| DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
| EP1401849A4 (en) | 2001-05-30 | 2005-05-18 | Chromos Molecular Systems Inc | ARTIFICIAL PLANT CHROMOSOMES, THEIR USE AND METHOD FOR THE MANUFACTURE OF ARTIFICIAL PLANT CHROMOSOMES |
| IL157746A0 (en) | 2001-05-30 | 2004-03-28 | Chromos Molecular Systems Inc | Chromosome-based platforms |
| CA2449591A1 (en) | 2001-06-11 | 2002-12-19 | Jurgen Peter Lode Del-Favero | Brain expressed gene and protein associated with bipolar disorder |
| US6638722B2 (en) | 2001-06-13 | 2003-10-28 | Invitrogen Corporation | Method for rapid amplification of DNA |
| WO2003006610A2 (en) | 2001-07-09 | 2003-01-23 | Diversa Corporation | Thermostable phosphatases and methods of making and using them |
| EP1513860A2 (en) | 2001-08-03 | 2005-03-16 | Diversa Corporation | P450 enzymes, nucleic acids encoding them and methods of making and using them |
| WO2003012126A2 (en) | 2001-08-03 | 2003-02-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
| AU2002331777A1 (en) | 2001-08-30 | 2003-03-18 | Spectral Genomics, Inc. | Arrays comprising pre-labeled biological molecules and methods for making and using these arrays |
| CA2458303A1 (en) | 2001-09-17 | 2003-03-27 | Janssen Pharmaceutica N.V. | Brain expressed cap-2 gene and protein associated with bipolar disorder |
| ATE533856T1 (de) | 2001-09-27 | 2011-12-15 | Perkinelmer Las Inc | Verfahren zum nachweis genetischer mosaike mit arrays |
| AU2002367886B8 (en) | 2001-10-12 | 2008-08-14 | Perkinelmer Las, Inc. | Compilations of nucleic acids and arrays and methods of using them |
| US7435871B2 (en) * | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
| US20030124542A1 (en) | 2001-12-28 | 2003-07-03 | Spectral Genomics, Inc. | Methods for mapping the chromosomal loci of genes expressed by a cell |
| EP1465986A4 (en) * | 2001-12-29 | 2005-01-26 | Woo Suk Hwang | GFP-TRANSFECTED CLONING PIG, GT-KNOCKOUT CLONING PIG, AND METHOD FOR THE MANUFACTURE THEREOF |
| US7482332B2 (en) | 2002-01-04 | 2009-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Telomere-encoding synthetic DNA nanocircles, and their use for the elongation of telomere repeats |
| CN101287827A (zh) | 2002-01-28 | 2008-10-15 | 戴弗萨公司 | 具有二级酰胺酶活性的酶及其应用方法 |
| AU2003219994B2 (en) | 2002-03-04 | 2009-04-09 | The Texas A & M University System | Quantitative trait loci and somatostatin |
| ATE471382T1 (de) | 2002-04-10 | 2010-07-15 | Us Gov Health & Human Serv | Vac-bac-shuttlevektor-system |
| CA2495787A1 (en) | 2002-05-01 | 2003-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| ATE464389T1 (de) | 2002-05-17 | 2010-04-15 | Kyowa Hakko Kirin Co Ltd | Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind |
| CA2487897A1 (en) | 2002-05-31 | 2003-12-11 | University Of Rochester | Helper virus-free herpesvirus amplicon particles and uses thereof |
| WO2004007750A2 (en) | 2002-07-11 | 2004-01-22 | Diversa Corporation | Monooxygenases, nucleic acids encoding them and methods for making and using them |
| WO2004009788A2 (en) | 2002-07-19 | 2004-01-29 | Diversa Corporation | Fluorescent proteins, nucleic acids encoding them and methods for making and using them |
| US20060252156A1 (en) | 2002-08-01 | 2006-11-09 | Evolva Ltd. C/O Dr. Iur. Martin Eisenring | Methods of mixing large numbers of heterologous genes |
| AU2003257155A1 (en) | 2002-08-02 | 2004-02-23 | The General Hospital Corporation | Methods for the production of cells and mammals with desired genetic modifications |
| EP1534819B1 (en) | 2002-08-21 | 2009-12-09 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
| US7414119B2 (en) | 2002-09-20 | 2008-08-19 | Verenium Corporation | Aldolases, nucleic acids encoding them and methods for making and using them |
| CN1717483A (zh) | 2002-10-04 | 2006-01-04 | 麒麟麦酒株式会社 | 人类人工染色体(hac)载体 |
| EP1578935A2 (en) | 2002-10-10 | 2005-09-28 | Diversa Corporation | Proteases, nucleic acids encoding them and methods for making and using them |
| US20060281908A1 (en) | 2002-11-06 | 2006-12-14 | Walter Callen | Xylose isomerases, nucleic acids encoding them and methods for making and using them |
| AU2003290689A1 (en) | 2002-11-08 | 2004-06-03 | Kyowa Hakko Kirin Co., Ltd. | Transgenic ungulates having reduced prion protein activity and uses thereof |
| AU2002952993A0 (en) | 2002-11-29 | 2002-12-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic and diagnostic agents |
| WO2004066945A2 (en) | 2003-01-24 | 2004-08-12 | Diversa Corporation | Enzymes and the nucleic acids encoding them and methods for making and using them |
| EP1639083A4 (en) * | 2003-06-06 | 2008-05-28 | Univ Pittsburgh | GENE OF CMP-N-ACETYLNEURAMIC ACID HYDROXYLASE FROM PIG |
| AU2004290006A1 (en) * | 2003-11-05 | 2005-05-26 | University Of Pittsburgh | Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region |
| AU2005243169A1 (en) * | 2004-05-07 | 2005-11-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Porcine Forssman synthetase protein, cDNA, genomic organization, and regulatory region |
| DK2348827T3 (en) * | 2008-10-27 | 2015-07-20 | Revivicor Inc | IMMUNICIPLY COMPROMATED PETS |
-
2005
- 2005-10-24 ES ES12161321.0T patent/ES2679282T3/es not_active Expired - Lifetime
- 2005-10-24 US US11/257,817 patent/US20060130157A1/en not_active Abandoned
- 2005-10-24 NZ NZ554824A patent/NZ554824A/en not_active IP Right Cessation
- 2005-10-24 CA CA2585098A patent/CA2585098C/en not_active Expired - Lifetime
- 2005-10-24 CA CA3079874A patent/CA3079874C/en not_active Expired - Lifetime
- 2005-10-24 EP EP05818708A patent/EP1811832A4/en not_active Withdrawn
- 2005-10-24 CA CA2958259A patent/CA2958259C/en not_active Expired - Lifetime
- 2005-10-24 CN CNA2005800441766A patent/CN101389214A/zh active Pending
- 2005-10-24 KR KR1020077011667A patent/KR20070072608A/ko not_active Withdrawn
- 2005-10-24 JP JP2007538187A patent/JP2008517608A/ja not_active Withdrawn
- 2005-10-24 EP EP12161321.0A patent/EP2527456B1/en not_active Expired - Lifetime
- 2005-10-24 AU AU2005299413A patent/AU2005299413A1/en not_active Abandoned
- 2005-10-24 WO PCT/US2005/038582 patent/WO2006047603A2/en not_active Ceased
-
2012
- 2012-07-20 JP JP2012161653A patent/JP2012196234A/ja not_active Withdrawn
-
2015
- 2015-05-29 JP JP2015109486A patent/JP2015154786A/ja not_active Withdrawn
-
2018
- 2018-03-06 JP JP2018039628A patent/JP7058522B2/ja not_active Expired - Lifetime
-
2021
- 2021-10-01 JP JP2021162704A patent/JP7308243B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP7308243B2 (ja) | 2023-07-13 |
| JP2015154786A (ja) | 2015-08-27 |
| ES2679282T3 (es) | 2018-08-23 |
| WO2006047603A3 (en) | 2007-05-18 |
| US20060130157A1 (en) | 2006-06-15 |
| EP1811832A4 (en) | 2009-12-30 |
| JP2021192647A (ja) | 2021-12-23 |
| NZ554824A (en) | 2010-10-29 |
| CN101389214A (zh) | 2009-03-18 |
| CA2585098A1 (en) | 2006-05-04 |
| JP2008517608A (ja) | 2008-05-29 |
| CA2958259C (en) | 2020-06-30 |
| JP2012196234A (ja) | 2012-10-18 |
| EP1811832A2 (en) | 2007-08-01 |
| CA2958259A1 (en) | 2006-05-04 |
| CA3079874A1 (en) | 2006-05-04 |
| WO2006047603A2 (en) | 2006-05-04 |
| CA2585098C (en) | 2018-12-18 |
| CA3079874C (en) | 2023-01-03 |
| JP2018086031A (ja) | 2018-06-07 |
| EP2527456B1 (en) | 2018-05-16 |
| JP7058522B2 (ja) | 2022-04-22 |
| EP2527456A1 (en) | 2012-11-28 |
| AU2005299413A1 (en) | 2006-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2585098C (en) | Porcine genomic kappa and lambda light chain sequences | |
| US11085054B2 (en) | Ungulates with genetically modified immune systems | |
| KR101924805B1 (ko) | 인간화 경쇄 마우스 | |
| KR102506001B1 (ko) | 하이브리드 경쇄 마우스 | |
| AU2014271342B2 (en) | Ungulates with genetically modified immune systems | |
| ES2548377T3 (es) | Ungulados inmunodeprimidos | |
| Chi et al. | Expression of Nkx2‐5‐GFP bacterial artificial chromosome transgenic mice closely resembles endogenous Nkx2‐5 gene activity | |
| US20040265806A1 (en) | Position-independent and tissue specific expression of a transgene in milk of transgenic animals | |
| RU2833566C2 (ru) | МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРИАБЕЛЬНОЙ ОБЛАСТЬЮ λ ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20070522 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |